{
    "clinical_study": {
        "@rank": "31994", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give adefovir dipivoxil\n      plus abacavir (ABC) plus efavirenz (EFV) plus amprenavir (APV) to HIV-infected patients who\n      have failed to respond to previous treatment with protease inhibitors (PIs)."
        }, 
        "brief_title": "Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive a treatment regimen of adefovir dipivoxil, abacavir, efavirenz, and\n      amprenavir for 24 weeks. During the study, patients are evaluated for changes from baseline\n      in plasma HIV-1 RNA levels and lymphocyte subsets and for development of adverse events and\n      toxicities.  Patients who experience virologic failure are discontinued from the study.\n      After Week 24, patients with documented virologic response are eligible to continue\n      receiving the study treatment and to attend scheduled follow-up visits."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are HIV-positive.\n\n          -  Had an HIV level of at least 2,000 copies/ml after 6 months of treatment with at\n             least 1 PI other than amprenavir (meaning you failed PI treatment).\n\n          -  Are at least 13 years old (need consent of parent or guardian if under 18).\n\n          -  Are able to complete the study.\n\n          -  Agree to use effective barrier methods of birth control, such as condoms, during the\n             study.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Have certain serious medical conditions, including AIDS-related cancers (except\n             Kaposi's sarcoma) that require treatment during the study.\n\n          -  Have ever taken or are allergic to adefovir dipivoxil, ABC, APV, EFV.\n\n          -  Are participating in another anti-HIV drug trial during this study.\n\n          -  Have taken certain medications within 30 days prior to study entry, including\n             medications that affect your immune system.\n\n          -  Have been diagnosed with hepatitis within the past 30 days.\n\n          -  Abuse alcohol or drugs.\n\n          -  Are pregnant or breast-feeding.\n\n          -  Have ever taken NNRTIs.\n\n          -  Have ever taken ddI or d4T.\n\n          -  Have received chemotherapy or radiation therapy within 30 days prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "25", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002419", 
            "org_study_id": "299A", 
            "secondary_id": "ICC 605"
        }, 
        "intervention": [
            {
                "intervention_name": "Abacavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Adefovir dipivoxil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Amprenavir", 
                "HIV Protease Inhibitors", 
                "Adefovir", 
                "Adefovir dipivoxil", 
                "Efavirenz", 
                "Abacavir", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90211"
                    }, 
                    "name": "Pacific Oaks Med Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "Univ of Colorado / Health Science Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02908"
                    }, 
                    "name": "Brown Univ School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hampton", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23666"
                    }, 
                    "name": "Hampton Roads Med Specialists"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of Novel Quadruple-Combination Therapy With Preveon (Adefovir Dipivoxil; Bis-POM PMEA), Abacavir (1592U89), Sustiva (Efavirenz; DMP-266), and Amprenavir (141W94) for the Treatment of HIV-1 Infection in Patients Who Have Failed Previous Protease Inhibitor Treatment", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002419"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Glaxo Wellcome", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Dupont Applied Biosciences", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1999"
    }, 
    "geocoordinates": {
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "Brown Univ School of Medicine": "41.824 -71.413", 
        "Hampton Roads Med Specialists": "37.03 -76.345", 
        "Pacific Oaks Med Group": "34.074 -118.4", 
        "Univ of Colorado / Health Science Ctr": "39.739 -104.985"
    }
}